Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro
- PMID: 1430102
- DOI: 10.1007/BF00920789
Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro
Abstract
Intravenous immunoglobulin is used to an increasing extent in various immune-mediated diseases, but its mechanism(s) of action in vivo is incompletely understood. Previous studies have shown that intravenous immunoglobulin may interfere with autoantibodies and their production by B cells and also inhibit Fc-mediated antibody-dependent cytotoxicity. Here we describe a novel effect of intravenous immunoglobulin on proliferation of in vitro activated peripheral blood lymphocytes and autonomously growing cell lines of various origin. Independently of whether proliferation was autonomous or induced by antigen-specific or antigen-nonspecific reagents, proliferation was inhibited in a dose-dependent fashion, as measured by reduced 3H-thymidine and BrdU uptake and cell counting. The effect was not due to cytotoxic effects of intravenous immunoglobulin and was reversible after removing the intravenous immunoglobulin by washing. The IgG levels required for this inhibition of proliferation are supraphysiological but are reached in vivo during treatment with intravenous immunoglobulin.
Similar articles
-
Intravenous immunoglobulin G-mediated inhibition of T-cell proliferation reflects an endogenous mechanism by which IgG modulates T-cell activation.Clin Immunol. 2009 Aug;132(2):222-33. doi: 10.1016/j.clim.2009.04.002. Epub 2009 May 17. Clin Immunol. 2009. PMID: 19447680
-
Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells.Clin Immunol. 2015 Oct;160(2):123-32. doi: 10.1016/j.clim.2015.05.003. Epub 2015 May 14. Clin Immunol. 2015. PMID: 25982320
-
Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production.Clin Exp Immunol. 2009 Oct;158(1):99-105. doi: 10.1111/j.1365-2249.2009.03996.x. Clin Exp Immunol. 2009. PMID: 19737236 Free PMC article.
-
Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders.BioDrugs. 2002;16(1):47-55. doi: 10.2165/00063030-200216010-00005. BioDrugs. 2002. PMID: 11909001 Review.
-
[Regulation of immunoglobulin production: role of the cellular receptors for the Fc portion of these molecules].Ann Immunol (Paris). 1982 Sep-Oct;133D(2):199-210. Ann Immunol (Paris). 1982. PMID: 6219609 Review. French.
Cited by
-
IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice.Clin Exp Immunol. 2006 Jul;145(1):108-15. doi: 10.1111/j.1365-2249.2006.03098.x. Clin Exp Immunol. 2006. PMID: 16792680 Free PMC article.
-
In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency.Clin Exp Med. 2010 Mar;10(1):27-31. doi: 10.1007/s10238-009-0061-1. Clin Exp Med. 2010. PMID: 19730984
-
Role of HLA-I Structural Variants and the Polyreactive Antibodies They Generate in Immune Homeostasis.Antibodies (Basel). 2022 Sep 8;11(3):58. doi: 10.3390/antib11030058. Antibodies (Basel). 2022. PMID: 36134954 Free PMC article. Review.
-
The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.J Clin Immunol. 1997 Jul;17(4):301-10. doi: 10.1023/a:1027326731945. J Clin Immunol. 1997. PMID: 9258769
-
In vivo modulation of cytokine synthesis by intravenous immunoglobulin.Clin Exp Immunol. 1999 Jun;116(3):509-15. doi: 10.1046/j.1365-2249.1999.00924.x. Clin Exp Immunol. 1999. PMID: 10361243 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources